Brand names: BIKTARVY (in combination)
Bictegravir is indicated for:
Human immunodeficiency virus-1 (HIV-1)
Irrespective of gender only Adults (18 - 65 years old)
Bictegravir is indicated for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1).
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 50 mg once daily
Active ingredient Bictegravir is contraindicated in the following cases:
Strong inducers of CYP3A and UGT1A1
No gender/age discrimination
Bictegravir is a substrate of CYP3A and UGT1A1. Co-administration of bictegravir and medicinal products that potently induce both CYP3A and UGT1A1, such as rifampicin or St. John’s wort, may significantly decrease plasma concentrations of bictegravir, which may result in a loss of therapeutic effect of Biktarvy and development of resistance, therefore co-administration is contraindicated. Co-administration of bictegravir with medicinal products that potently inhibit both CYP3A and UGT1A1, such as atazanavir, may significantly increase plasma concentrations of bictegravir, therefore co-administration is not recommended.